Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate Vs Azathioprine or Adalimumab for Maintaining Remission in Patients At Low or High Risk for Aggressive Disease Course, Respectively-a Treatment Strategy

NCT02852694 is registered in ClinicalTrials.gov with PIBD-Net as lead sponsor.

NCT NCT02852694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02852694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate Vs Azathioprine or Adalimumab for Maintaining Remission in Patients At Low or High Risk for Aggressive Disease Course, Respectively-a Treatment Strategy
Lead sponsor
PIBD-Net
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2017
Completion date
June 14, 2021
Enrollment
192 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease